GSK Update on FDA Review of Promacta(R) (El... ( PHILADELPHIA Pa. June 20 /- Glaxo...)

GSK Update on FDA Review of Promacta(R) (Eltrombopag)

Date:6/20/2008

PHILADELPHIA, Pa. June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008.

On May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura, or ITP.

GSK will continue to work with the FDA towards the approval of eltrombopag in order to provide physicians and chronic ITP patients with a novel option for treating this difficult disease.

About Promacta(R) (Eltrombopag)

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding. In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

US Media inquiries: Jeff McLaughlin 1 919 483 2839
'/>"/>

0

GOOD

Page: 1 2
Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Genmab Announces Updates on Phase III Cancer Studies
5. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
8. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
9. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
10. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
11. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

Post Your Comments:

GSK Update on FDA Review of Promacta(R) (El...( PHILADELPHIA Pa. June 20 /- Glaxo...),Health